Targeting the Microbiome


Cambridge Healthtech Institute 第3届
微生物群标靶化
透过微生物群治疗法开发的新药开发标靶发现

第15届Discovery on Target其中一环

本会议以微生物群的标靶化为主题,将分享来自微生物群的生物标记、新药发现标靶、生物活性分子的发现与开发相关研究面及临床面成果,讨论作为炎症、代谢失调、消化道疾病、肥胖、2型糖尿病、自体免疫疾病、炎症性大肠炎、神经发展障碍症等慢性疾病治疗法的可能性。透过互动会议及小组讨论,主要研究人员及意见领袖将讨论微生物群如何成为影响疾病进展的治疗介入重要要点。

Final Agenda



7:00 am Registration Open and Morning Coffee

Targeting the Gut Microbiome in Health & Disease: Market Trends, Data Analysis, and Standards

8:00 Welcome Remarks

Cindy Crowninshield, RDN, LDN, HHC, Senior Conference Director, Cambridge Healthtech Institute

8:05 Chairperson's Opening Remarks

Sudeep Basu, Ph.D., Practice Leader, TechVision-Innovation Services, Frost & Sullivan

8:10 Human Microbiome Growth Opportunities and Predictions

Sudeep Basu, Ph.D., Practice Leader, TechVision-Innovation Services, Frost & Sullivan

This presentation focuses on recent development in the areas of microbiome-driven therapeutics. An overview of key research groups, disease focus areas and trends will be provided. The discussion will encompass a review of select technologies, markets and products as well.

8:40 The Human Microbiome: Data Challenges and Solutions

Andreas M. Kogelnik, M.D., Ph.D., Director, Open Medicine Institute

Human microbiome analysis is the study of microbial communities found in and on the human body. The goal of human microbiome studies is to understand the role of microbes in health and disease. High throughput methods have enabled increasingly relevant studies with increasing clinical impact that is both surprising and broad-reaching at times. There remains enormous work to be done for data analysis and for application of these technologies.

9:10 Standards for Microbiome and Metagenomics: Supporting the Commercial Translation of Microbiome Science

Scott Jackson, Ph.D., Molecular Genetics and Microbial Genomics, National Institute of Standards and Technology

At NIST, we are improving microbiome science and supporting the National Microbiome Initiative by developing standards for microbiome measurements that will enable federal, academic, and industry labs to reliably reproduce and advance each other's results. Microbiome standards will support research investigations and commercial translation of microbiome science by providing measurement assurance tools: standardized protocols, reference materials, validated measurements and critically evaluated reference data.

9:40 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

Novel Therapeutic Targets Based on Microbiome R&D, Part I

10:25 Designing Targeted Next Generation Microbial Therapeutics for Inflammatory Diseases

Nikole Kimes, Ph.D., Co-founder and Vice President, Siolta Therapeutics

The burgeoning field of microbial therapeutics represents an exciting class of biologics that hold great potential for the prevention and treatment of inflammatory diseases. Siolta Therapeutics is particularly focused on the rational design of a mixed-species microbial consortium to treat childhood asthma through the reengineering of the gut microbiome. Our multifaceted approach utilizes patient stratification, immune phenotyping, and rationally designed microbial consortia to provide next generation microbial therapeutics.

10:55 Role of Probiotics to Prevent Viral Chronic Diseases

Imad Al Kassaa, Ph.D., Associate Professor, Microbiology, Lebanese University; Researcher, Laboratoire Microbiologie Sante et Environnement (LMSE)

In this presentation, we discuss the possible role of probiotic strains in chronic viral infections and their benefits in therapy strategies against infectious diseases. Data from numerous studies has shown that the use of probiotic as therapeutic agents is safe and inexpensive and can avoid the need for invasive treatment for several chronic viral infections caused by HIV, HCV, HTLV, HPV, CVB4, etc.

11:25 Subtractive Assembly Approaches for Identification of Disease-Associated Microbial Marker Genes

Yuzhen Ye, Ph.D., Associate Professor, Computer Science, Indiana University, Bloomington

We have developed novel computational approaches for identification of disease-associated microbial marker genes from metagenomic and metatranscriptomic datasets. Application of our approaches to the microbiome datasets associated with type II diabetes and liver cancer demonstrated that our approaches provide simplified yet efficient solutions for identification of disease-related microbial marker genes.

11:55 Presentation to be Announced

12:25 pm Session Break

12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

1:50 Chairperson's Remarks

Susan K. Finston, Esq., CEO and Managing Director, Amrita Therapeutics

1:55 Clinical Development of Ammonia Oxidizing Bacteria for Systemic and Dermatologic Targets

Larry Weiss, CMO, AOBiome, LLC

AOBiome is a clinical stage microbiome therapeutics company in Phase II development with a range of systemic and dermatologic therapeutic targets including acne, hypertension, allergic rhinitis, and migraine headache. Our intervention is based on restoring ammonia oxidizing bacteria (AOB), and autotrophic ancestral keystone commensal bacteria. This bacteria oxidize physiologic ammonia to nitrite and nitric oxide restoring host control over local and systemic inflammation, hemodynamics, and cellular energy metabolism. We will present scientific and clinical data.

Targeting the Gut Microbiome in Health & Disease: Patent Eligibility and Investment Opportunities

2:25 IP Challenges and Opportunities for Microbiome Inventions

Susan K. Finston, Esq., CEO and Managing Director, Amrita Therapeutics

Patentability of novel life forms like the famous 'Chakrabarty molecule' launched the American Biotechnology Revolution in the 1980s. Now in 2017 the microbiome is the biotech frontier, however doubts had arisen around patentability of microbiome technologies. Fortunately the judiciary and USPTO appear to understand the critical importance of preserving patent incentives for emerging technologies; through careful and painstaking patent prosecution, microbiome technologies are eminently patentable.

2:55 Sponsored Presentation (Opportunity Available)

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing and Poster Competition Winner Announced

4:05 PANEL DISCUSSION: From Microbiome to Market: Exploring Global Scope of Microbiome and Successful Collaboration, Reimbursement, and Business Investment Models

Moderator: Keith F. Batchelder, M.D., CEO and Founder, Genomic Healthcare Strategies

Panelists: Jonathan Freeman, Chief Business Officer, Vedanta

Greg Sieczkiewicz, J.D., Ph.D., Chief IP Counsel, MPM

Cameron Wheeler, Ph.D., Principal, Deerfield Management

Additional Panelists to be Announced

This microbiome to market panel discussion serves as a critical ending to the first day of this meeting. Today's agenda has covered themes related to market trends, data analysis, standards, IP challenges, and targeting next generation microbial therapeutics. This panel discussion is appropriate for you if you are working in research, science or industry and have questions about translation opportunities or the kinds of business and financial models that investors find attractive. Leading investors will gather to discuss the areas of the microbiome they are looking at and why. We will explore the global scope of microbiome and successful collaboration, reimbursement, and business investment models between science, business, healthcare, and government in bringing live microbial products to market. We will also discuss balancing venture activities, external R&D, and long-term market opportunities. Join us for a lively and interactive discussion of the how's and what's of bringing your microbiome product or service to market.

5:05 Interactive Breakout Discussion Groups

Join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Details on the topics and moderators are available on the conference website.

6:05 Welcome Reception in the Exhibit Hall (Sponsorship Opportunity Available)

7:10 Close of Day

Wednesday, September 27

7:30 am Registration Open and Morning Coffee

Novel Therapeutic Targets Based on Microbiome R&D, Part II

8:00 Chairperson's Remarks

Bonnie Feldman, D.D.S., MBA, Digital Health Analyst and Chief Growth Officer, DrBonnie360

8:05 Precision Microbiota Applications in Clinical Therapy and Diagnosis

Lynn Bry, M.D., Ph.D., FCAP, Director, Massachusetts Host-Microbiome Center, Pathology, Brigham & Women's Hospital, Harvard Medical School

The microbiota, or compending of organisms living on and in us, provide essential functions for normal health and physiology. They also contribute to a variety of diseases. This non-human organ is also increasingly being used to develop and target new therapies for a variety of conditions, from Clostridium difficile colitis, to treatment of IBD, and other autoimmune, allergic and metabolic diseases.

8:35Discovering Microbiome-Related Nutritional Biomarkers for Chronic Diseases Using Multi-Omics and Transgenic Model Technologies

Kanakaraju Kaliannan, M.D., Senior Research Fellow, Laboratory for Lipid Medicine and Technology (LLMT), Massachusetts General Hospital

The modern chronic disease epidemic has coincided with the rise of nutritional imbalances in the Western diet, including excessive intake of omega-6 fatty acids and insufficient intake of omega-3 fatty acids. Our combined use of multi-omics technologies with novel transgenic mouse models has demonstrated critical links between the omega-6/omega-3 fatty acid imbalance and chronic disease, and has discovered microbiome-derived biomarkers for disease assessment. Targeting the microbiome is a key approach for developing effective therapeutics for chronic disease.

9:05 Sponsored Presentation (Opportunity Available)

9:35 Coffee Break in the Exhibit Hall with Poster Viewing

10:20 The 7-Day Forecast for Our Health Storm: Exploring the Connection between the Oral Microbiome and Immune-Mediated Inflammatory Diseases, and Personalized Nutrition

Bonnie Feldman, D.D.S., MBA, Digital Health Analyst and Chief Growth Officer, DrBonnie360

The status of our oral health may be an early indicator of other systemic diseases such as diabetes, heart disease, stroke, rheumatoid arthritis and other autoimmune diseases. This talk will present the latest research done on the connection of the oral microbiome to chronic and autoimmune diseases, as well as discuss implementation of the research on the emerging field of personalized nutrition.

10:50 Targeting the Intestinal Microbiome with Colon-Specific Pharmaceutical Vehicles - Revisiting

Abraham Rubinstein, Ph.D., Professor, Institute for Drug Research, The Hebrew University of Jerusalem School of Pharmacy

The enormous number of microorganisms inhabiting the human intestine, mainly the large bowel, is a source for diverse enzymatic activity that can be exploited for drug delivery and imaging purposes. Polymeric vehicles, susceptible to enzyme-driven hydrolysis have been suggested and tested clinically in the context of local treatment of colon-mucosa associated diseases and imaging.

11:20 Enjoy Lunch on Your Own

12:20 pm Plenary Keynote Program

(click here for details)

2:00 Refreshment Break in the Exhibit Hall with Poster Viewing

2:45 Close of Conference

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English

Catalog

Celebrating 25 Years

Submit A Poster

View All Sponsors

View Media Partners



免费电子邮件通知服务